^
Association details:
| Biomarker: | DDR |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | abiraterone acetate (CYP17A1 inhibitor) + prednisone (Steroid receptor agonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
EVALUATION OF MARKERS ASSOCIATED WITH EFFICACY OF ABIRATERONE ACETATE PLUS PREDNISONE (AAP) IN PATIENTS (PTS) WITH CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC) FROM THE LATITUDE STUDY
Published date:
09/30/2019
Excerpt:
In the AAP arm, shorter PFS was observed for DRD+ vs DRD– cohort (median 21.01 vs 24.14 mo; HR: 3.9; 95% CI: 1.1-12.1; p = 0.03)…The DRD+ cohort appears to show poorer rPFS outcome in AAP treated men.
Trial ID:
